Thus, fluoroquinolone use is typically reserved for cases in which the benefits clearly outweigh the risks. The spectrum of activity, mechanisms of action and resistance, important resistance patterns, and adverse effects of commonly available fluoroquinolones (ie, ciprofloxacin, levofloxacin, moxifloxacin, delafloxacin) will be reviewed here.

BENEFITS AND RISKS OF USE Restriction of use for uncomplicated infections — In general, we find that the risks of fluoroquinolone use outweigh the benefits for the treatment of uncomplicated infections such as acute rhinosinusitis, uncomplicated cystitis, and acute bronchitis.

UpToDate ... UpToDate

2023年12月1日 · INTRODUCTION External otitis, also known as otitis externa or swimmer's ear, refers to inflammation of the external auditory canal or auricle. This topic will focus on the treatment of external otitis. The pathogenesis, clinical manifestations, and diagnosis of external otitis are discussed elsewhere. (See "External otitis: Pathogenesis, clinical features, and …

Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review.

CONCLUSIONS AND RELEVANCE Use of fluoroquinolones was associated with an increased risk of aortic aneurysm and dissection. While these were rare events, physicians should be aware of this possible drug safety risk associated with fluoroquinolone therapy. AD

Drug-specific risk analyses focused on three fluoroquinolone agents (ciprofloxacin, levofloxacin, and moxifloxacin) indicated a significant association between ciprofloxacin use and an increased risk of hepatotoxicity (OR, 1.29; 95% CI, 1.05-1.58); when considered as independent variables, levofloxacin use and moxifloxacin use were not ...

Comprehensive guide on treating enterococcal infections, including diagnosis and management strategies.

Fluoroquinolone use was associated with a statistically significant 85% increase in the risk for arrhythmia (odds ratio [OR]1.85; 95% confidence interval [CI]1.22-2.81) and 71% increase in the risk for cardiovascular mortality (OR 1.71; 95% CI 1.39-2.09).

2022年11月7日 · Treatment options include high-dose amoxicillin-clavulanate (2 g/125 mg extended-release tablets orally twice daily), a respiratory fluoroquinolone (levofloxacin 500 mg orally once daily or moxifloxacin 400 mg orally once daily), or a third-generation cephalosporin plus clindamycin.